Boehringer Ingelheim

...32 cents per share on revenue of $46.6 million. Exelixis said the revenue boost came from new partnerships with Sanofi-Aventis and Bristol-Myers Squibb on potential cancer treatments and Boehringer Ingelheim on autoimmune disease treatments.

In this article: Revenue, Cancer, Autoimmune disease, Thomson Reuters, Bristol-Myers Squibb, Sanofi-Aventis, and South San Francisco, Calif.

...million in China with the goal of increasing its market share in China and the Far East. The company will use the money to expand capacity at its existing drug production facility in Shanghai's Zhangjiang High-Tech Park, and it will also...

In this article: China, OSI Pharmaceuticals, Human papillomavirus, Forbes Magazine, and Far East

...of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara((R)). Peregrine also has in-house manufacturing...

In this article: Avid, Monoclonal antibodies, Business operations, and Cancer

...treatment specifically designed for dogs and will be retained by Pfizer, Campion said. Boehringer Ingelheim will also acquire research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and intellectual...

In this article: Pfizer Inc, Wyeth, Revenue, United States, Cattle, Dog, Cancer, and Palladia

...and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in...

In this article: Cancer, Lung cancer, Eastern Cooperative Oncology Group, Pemetrexed, Adenocarcinoma, Docetaxel, Tyrosine, Graduate Institute, and Angiogenesis inhibitor

...in 47 countries. Boehringer Ingelheim has a dedicated cancer research center in Vienna where scientists are focused on the discovery and development of new treatments to combat or alleviate the symptoms of cancer. Clinical trial...

In this article: Lung cancer, Cancer, Eastern Cooperative Oncology Group, Adenocarcinoma, Docetaxel, Tyrosine, Graduate Institute, Medical advice, and Angiogenesis inhibitor

...Switzerland. BIBF 1120, administered as a capsule taken twice daily, is currently being developed by Boehringer Ingelheim and is one of the company's most advanced molecules within the cancer development portfolio. BIBF 1120 is a novel...

In this article: Cancer, Pemetrexed, Carboplatin, Paclitaxel, Lung cancer, Vegfrs, Geneva, and Germany

...NSCLC.5 In the emerging era of personalised cancer medicine, Boehringer Ingelheim is one of the first companies to prospectively identify appropriate patients for clinical trials based on biomarkers. As part of the LUX-Lung...

In this article: Cancer, Ovarian cancer, Lung cancer, Gefitinib, Erlotinib, HER2, and Adenocarcinoma

...blocking a part of the cell's make-up that is crucial for cell division. BI 6727 is one in a series of compounds being developed by Boehringer Ingelheim in this field. By inhibiting the activity of Polo-like kinase 1 (Plk1), which is highly...

In this article: Cancer, Chronic myelogenous leukemia, Polo-like kinase 1, Neuropathy, and Ingelheim